World neurosurgery · 2019
Interleaving Stimulation in Parkinson Disease: Interesting to Whom?
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
França Carina, Barbosa Egberto Reis, Iglesio Ricardo, Teixeira Manoel Jacobsen, Cury Rubens Gisbert
Аннотация
BACKGROUND: Interleaving stimulation (ILS) is a stimulation strategy that can help the physician manage more challenging cases of patients with deep brain stimulation (DBS) for Parkinson disease (PD). It consists of altering 2 different programs on the electrode with the same frequency.
OBJECTIVES: Our objective was to overview our patients' experience with ILS and explore clinical scenarios in which ILS should be considered when programming DBS in patients with PD.
METHODS: We retrospectively reviewed medical charts from 120 patients with PD treated with DBS between 2011 and 2018.
RESULTS: Eighteen patients received ILS. One was excluded because of the medical chart was incomplete. The remaining 17 patients had subthalamic nucleus DBS (n = 14) and globus pallidus internus DBS (n = 3). Eight patients (47%) received ILS to improve rigidity and bradykinesia, 4 to improve dyskinesias, 4 because of refractory tremor, and 1 for gait management. Until the end of data collection, 13 of 17 patients (70%) were still on ILS, with a mean duration time of 28.8 months (range, 2-44 months). Four patients reported no benefit from ILS and had their program changed.
CONCLUSIONS: Overall, ILS is useful 1) to use 2 contacts that optimally improve 2 specific symptoms but have different therapeutic windows; 2) to avoid side effects related to current spreading to nearby areas; 3) to increase frequency in a small region; or 4) to stimulate a larger target area.
OBJECTIVES: Our objective was to overview our patients' experience with ILS and explore clinical scenarios in which ILS should be considered when programming DBS in patients with PD.
METHODS: We retrospectively reviewed medical charts from 120 patients with PD treated with DBS between 2011 and 2018.
RESULTS: Eighteen patients received ILS. One was excluded because of the medical chart was incomplete. The remaining 17 patients had subthalamic nucleus DBS (n = 14) and globus pallidus internus DBS (n = 3). Eight patients (47%) received ILS to improve rigidity and bradykinesia, 4 to improve dyskinesias, 4 because of refractory tremor, and 1 for gait management. Until the end of data collection, 13 of 17 patients (70%) were still on ILS, with a mean duration time of 28.8 months (range, 2-44 months). Four patients reported no benefit from ILS and had their program changed.
CONCLUSIONS: Overall, ILS is useful 1) to use 2 contacts that optimally improve 2 specific symptoms but have different therapeutic windows; 2) to avoid side effects related to current spreading to nearby areas; 3) to increase frequency in a small region; or 4) to stimulate a larger target area.